Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF KRESTIN (PSK) AS ADJUVANT TREATMENT ON THE PROGNOSIS AFTER RADICAL RADIOTHERAPY IN PATIENTS WITH NONSMALL CELL LUNG-CANCER
Autore:
HAYAKAWA K; MITSUHASHI N; SAITO Y; TAKAHASHI M; KATANO S; SHIOJIMA K; FURUTA M; NIIBE H;
Indirizzi:
GUNMA UNIV,SCH MED,DEPT RADIOL & RADIAT ONCOL,3-39-22 SHOWA MACHI MAEBASHI GUNMA 371 JAPAN
Titolo Testata:
Anticancer research
fascicolo: 5C, volume: 13, anno: 1993,
pagine: 1815 - 1820
SICI:
0250-7005(1993)13:5C<1815:EOK(AA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-TERM SURVIVORS; RADIATION-THERAPY; TUMOR-CONTROL; STAGE-I; CARCINOMA; IRRADIATION; IMPACT;
Keywords:
NONSMALL CELL LUNG CANCER; RADIOTHERAPY; BIOTHERAPY; ADJUVANT IMMUNOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
K. Hayakawa et al., "EFFECT OF KRESTIN (PSK) AS ADJUVANT TREATMENT ON THE PROGNOSIS AFTER RADICAL RADIOTHERAPY IN PATIENTS WITH NONSMALL CELL LUNG-CANCER", Anticancer research, 13(5C), 1993, pp. 1815-1820

Abstract

From 1976 to 1985, 185 patients with non-small cell lung cancer at stages I-III were treated with definitive radiotherapy in Gunma University Hospital. As a result of analyzing the long-term survivors treated with radiotherapy, suitable conditions of the patients for radical radiotherapy were as follows; I) stage I or II, and some stage III, 2) asregards the histologic type epider moid carcinoma or well-differentiated adenocarcinoma, 3) as regards the primary sites, the upper lobe and the superior segment of the lower lobe, 4) the optimum dose was 60-70Gy, 5) the size of the radiation fields given >40Gy was 100 cm(2) or less, and 6) the host condition was satisfactory (BRM combined use). In particular, as a result of administering PSK as adjuvant treatment to patients with epidermoid carcinoma of the lung showing satisfactory tumour shrinkage after radiotherapy, the five year survival late of the patients with stages I ar II disease as well as stage III was 39% and 22% respectively, compared with the non-administered group's 16% and5%. These differences are statistically significant. Although an improvement in the results of treatment with the combined use of appropriate BRMs is anticipated in the future, when clinical trials for combined BRM and radiotherapy are planned the subjects should be patients with satisfactory tumour regression after radiotherapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 12:00:01